Needham & Company analyst Alan Carr boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) from $9 to $16 it ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE